Previous article![]( "Top 25 Indian Pharma Companies by Revenues in 2024")
Next article![]( "India’s Medical Devices Market: Strategic Implications and Key Investors")
Wednesday, April 22, 2026
29.4
C
Bengaluru
Hot topics
Indian Pharma Market (IPM) Highlights – January 2025
Overall IPM Performance:
Monthly Growth: IPM monthly growth reached 8.4% in...
Making Peace with an Unlived Life – My Journey by Deep Bhandari
The Beginning
I was at crossroads after completing computer...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
ZS Bets Big on India as Pharma GCCs Rewrite the Global Life Sciences Playbook
With its latest expansion, ZS is placing a decisive...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Hot topics
Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future
For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
Are Indian Pharma Business Leaders Adopting Digital Transformation?
We will need to find a way to bring together the capabilities of the Medical Rep, the changed scenario of the visit and the ways we can reach doctors into one single strategy rather than looking at the physical and the digital parts separately. Our medical reps will continue to be the core of our promotion, and our digital strategy will need to empower them to not only do a better call but also support their efforts by building processes that will help them beyond the few minutes that they spend in the Clinic. Marketing budgets will have to move away from conventional investments and also think beyond hardware to increase digital engagement.
Mounjaro to Orforglipro: Lilly’s $6 Billion Bet on the Next GLP‑1 Revolution
Eli Lilly is in a rare position. Its GLP-1...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Will the GLP Battle Now Shift from Injectable to Oral?
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
The Semaglutide Shift: From Blockbuster to Commodity
Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
Newsletter
Get important news delivered directly to your inbox and stay connected!